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a b s t r a c t
Regulator of G protein signalling 2 (RGS2) is known to play a protective role in maladaptive cardiac hypertrophy
and heart failure via its ability to inhibit Gq- and Gs- mediated GPCR signalling. We previously demonstrated that
RGS2 can also inhibit protein translation and can thereby attenuate cell growth. This G protein-independent inhibitory effect has been mapped to a 37 amino acid domain (RGS2eb) within RGS2 that binds to eukaryotic initiation factor 2B (eIF2B). When expressed in neonatal rat cardiomyocytes, RGS2eb attenuates both protein
synthesis and hypertrophy induced by Gq- and Gs- activating agents. In the current study, we investigated the potential cardioprotective role of RGS2eb by determining whether RGS2eb transgenic (RGS2eb TG) mice with cardiomyocyte speciﬁc overexpression of RGS2eb show resistance to the development of hypertrophy in comparison to
wild-type (WT) controls. Using transverse aortic constriction (TAC) in a pressure-overload hypertrophy model,
we demonstrated that cardiac hypertrophy was inhibited in RGS2eb TG mice compared to WT controls following
four weeks of TAC. Expression of the hypertrophic markers atrial natriuretic peptide (ANP) and β-myosin heavy
chain (MHC-β) was also reduced in RGS2eb TG compared to WT TAC animals. Furthermore, cardiac function in
RGS2eb TG TAC mice was signiﬁcantly improved compared to WT TAC mice. Notably, cardiomyocyte cell size
was signiﬁcantly decreased in TG compared to WT TAC mice. These results suggest that RGS2 may limit pathological cardiac hypertrophy at least in part via the function of its eIF2B-binding domain.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Pathological cardiac hypertrophy is a maladaptive growth response
of the heart to a variety of disease stimuli. Induced by factors such as hypertension or valvular diseases, prolonged pathological hypertrophy
has been associated with an increased risk of sudden death, as well as
myocardial infarctions and arrhythmias [1–3]. Moreover, maladaptive
hypertrophy is a major risk factor for heart failure [3]. Given the high
mortality rates following heart failure diagnoses and the current lack
of a cure, reducing risk factors such as pathological cardiac hypertrophy
may prove therapeutically beneﬁcial.
G protein-coupled receptors (GPCRs) which signal via
heterotrimeric Gαq and Gαs proteins are well established as critical
players in the induction of pathological hypertrophy [3–5]. Clinically
Abbreviations: (eIF2), eukaryotic initiation factor 2; (eIF2B), eukaryotic initiation factor
2B; (GPCRs), G protein-coupled receptors; (HWT/BWT), heart weight/body weight; (LV),
left ventricle; (RGS2), regulator of G protein signalling 2; (RGS2eb), RGS2-eIF2B binding
domain; (TG), transgenic; (TAC), Transverse aortic constriction; (WT), wildtype.
⁎ Corresponding author at: Department of Physiology and Pharmacology, Medical
Sciences Building, University of Western Ontario, London, ON, N6A5C1, Canada.
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effective treatments for heart failure, such as angiotensin II converting
enzyme (ACE) inhibitors and beta-adrenergic receptor antagonists,
demonstrate the effectiveness of targeting Gq- and Gs- coupled receptors [6]. However, the effectiveness of these drugs is limited to slowing,
rather than reversing, the progression of heart failure. Regulator of G
protein signalling 2 (RGS2) is a GTPase accelerating protein (GAP)
found ubiquitously throughout the body. RGS2 selectively inhibits Gqand Gs-mediated signalling (some effects on Gi/o signalling have also
been reported [7,8]), thus making it an important target in the study
of cardiovascular disease [9–11]. Studies in vivo and in cardiomyocytes
have shown that hypertrophy caused by prolonged Gq-coupled receptor
stimulation, such as that induced by phenylephrine, can be blocked by
the overexpression of RGS2 [12,13]. A similar effect has been seen
against Gs-mediated cardiomyocyte hypertrophy induced by isoproterenol [14]. These observations suggest that RGS2 plays an important role
in the regulation of hypertrophy; this has been further demonstrated in
knockout animal studies. In RGS2 null mice, experimentally induced
pressure overload causes marked hypertrophy, heart failure, and
death, as well as increased expression of cardiac fetal genes [15]. Thus,
RGS2 would appear to be an essential element in the prevention of
pathological cardiac hypertrophy.

http://dx.doi.org/10.1016/j.yjmcc.2017.06.007
0022-2828/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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While the G protein inhibitory effects of RGS2 are well established,
studies have also shown that RGS2 can bind to and regulate other targets, including TRPV6 calcium channels and tubulin [16–18]. We have
previously shown that RGS2 can bind to the epsilon subunit of eukaryotic initiation factor 2B (eIF2B), a component of the rate-limiting step of
the initiation of mRNA translation [19]. By interacting with eIF2Bε, RGS2
limits GDP dissociation on eukaryotic initiation factor 2 (eIF2), which ultimately leads to the attenuation of de novo protein synthesis. This property of RGS2 has been mapped to a 37 amino acid domain (residues 79–
115) termed RGS2eb, that is homologous to a region in the beta subunit
of eIF2 [19].
Since the heart is considered to be a post-mitotic organ [20], hypertrophic growth is thought to be dependent on the enlargement of a preexisting cardiomyocyte population rather than cell division [21]. Therefore, regardless of the initial stimuli and receptors involved, all hypertrophic signals will ultimately result in increased mRNA translation
and de novo protein synthesis. Our previous studies have shown that
RGS2eb expression in cultured neonatal cardiomyocytes is able to inhibit
both protein synthesis and agonist induced hypertrophy at levels comparable to full-length RGS2 [22]. Based on these previous ﬁndings, we
hypothesized that the in vivo expression of RGS2eb in the murine heart
could attenuate the development of pathological cardiac hypertrophy.
To determine whether RGS2eb could act as an in vivo anti-hypertrophic
agent, we developed a line of transgenic mice with cardiomyocyte-speciﬁc overexpression of RGS2eb, and used transverse aortic constriction
(TAC) to induce pressure overload on the heart. Here we report that following 4 weeks of aortic constriction, RGS2eb transgenic mice were
protected against pressure overload-induced cardiac hypertrophy, and
also were able to maintain heart function at signiﬁcantly improved
levels compared to WT TAC mice. Moreover, reactivation of the “fetal
gene program”, an indicator of hypertrophy and heart failure, was suppressed. Notably, cardiomyocyte size was decreased in RGS2eb TG compared to WT TAC controls, further supporting our earlier in vitro studies
which showed RGS2eb inhibition of de novo protein synthesis. Together,
these ﬁndings suggest that in addition to its G-protein inhibitory actions, the RGS2eb region may be contributing to the cardioprotective effects of full-length RGS2 in vivo via the inhibition of de novo protein
synthesis.
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2.2. Transverse aortic constriction (TAC)
TAC was used to induce pressure overload on the hearts of 12 week
old male C57BL/6 wild-type mice and RGS2eb TG littermates. Mice were
anaesthetized with a ketamine (50 mg/kg) and xylazine (12.5 mg/kg)
cocktail intramuscularly, intubated, and ventilated with a respirator
(SAR-830, CWE, Ardmore, PA, USA). To access the chest cavity, thoracotomy was performed at the second intercostal space under a surgical microscope [25]. A 6–0 silk suture was placed between the brachiocephalic
and left carotid arteries. Two knots were tied against a 25-gauge blunt
needle placed parallel to the transverse aorta. The needle was removed
immediately after the second tied knot followed by closure of the chest.
Control WT and RGS2eb TG mice were subjected to sham operations
without aortic constriction.
2.3. Assessment of cardiac function
Hemodynamic measurements were performed as previously described [26,27]: four weeks post-surgery, mice were again anaesthetized with a ketamine and xylazine cocktail and ventilated. A Millar
micro-tip pressure catheter was inserted into the left carotid artery to
assess carotid artery pressure, followed by removal of the catheter and
insertion into the right carotid artery for pressure readings, and then advanced into the left ventricle (LV) to measure LV pressures, volumes,
and heart rate at steady state and during transient preload reduction
via mechanical occlusion of the inferior vena cava. All data were recorded using a PowerLab data acquisition system and analyzed by LabChart
7.0 (ADInstruments) and PVAN 3.4 software (Millar).
2.4. Heart weight/body weight ratios
Upon completion of hemodynamic recordings, mice were immediately euthanized via a 10% KCl injection into the left jugular vein to ensure cardiac arrest in the diastolic state. Hearts were excised, weighed
after removal of the atria, then cut transversely into three equal sections, with the middle section reserved for histological analysis, and
the remaining tissue sections stored at −80 °C for subsequent RNA
isolation.
2.5. Histological analysis

2. Materials and methods
2.1. Generation of myosin heavy chain promoter (MHC) - RGS2eb transgenic mice
The RGS2eb gene was targeted to the heart using the mouse α-MHC
promoter (kindly provided by Jeffrey Robbins, Cincinnati Children's
Hospital Medical Center) [23]. Transgenic mice were generated in the
FVB background (London Regional Transgenic and Gene Targeting Facility) and identiﬁed by polymerase chain reaction (PCR). Brieﬂy, ear biopsies were taken from three-week old mice and puriﬁed for genomic
DNA using the QIAquick PCR puriﬁcation kit (Qiagen). PCR was performed using DreamTaq Green PCR Master Mix (Thermo Scientiﬁc).
Primers for detection of transgenic mice (CTGCTAGCCAGCAAATATGGTC
forward, CCTACAGGTTGTCTTCCCAACT reverse) and control primers for
endogenous RGS2 expression (CCGAGTTCTGTGAAGAAAACATTG forward, ATGCTACATGAGACCAGGAGTCCC reverse) were designed using
the OligoPerfect Designer (ThermoFisher), OligoCalc [24], and PrimerBLAST (NCBI) programs, resulting in a 293 bp and 342 bp fragment, respectively. RGS2eb TG transgenic mice were back-crossed with C57Bl/6
mice (Charles River) for at least seven generations before animal experiments were performed. Animals were maintained in accordance with
the Institute of Laboratory Animal Research Guide for the Care and
Use of Laboratory Animals. These studies were approved by the Council
on Animal Care at the University of Western Ontario, and complied with
the guidelines of the Canadian Council on Animal Care.

Heart samples were ﬁxed in 4% paraformaldehyde overnight at 4 °C,
dehydrated, and parafﬁn embedded. Samples were sectioned into 5 μm
thick slices with a Leica RM2255 microtome, mounted onto positively
charged slides, and then stained with haematoxylin and eosin. Images
of left ventricles were captured at 400× magniﬁcation with a Zeiss Observer D1 microscope using AxioVision 4.7 software (Zeiss) for cardiomyocyte size measurements and immunohistochemical imaging;
images of the LV for wall thickness measurements were captured at
100× magniﬁcation.
2.6. Cardiomyocyte cell size and LV wall thickness
Haematoxylin and eosin stained tissue sections were used to determine left ventricular cardiomyocyte cell size and wall thickness of LV
free walls and septum. The size of an individual cardiomyocyte was determined by measuring its cross-sectional area. All cardiomyocytes with
a well-deﬁned border were manually outlined and then ﬁlled in the
open source GNU Image Manipulation Program (GIMP). Images were
then opened in the image processing program ImageJ and analyzed
after setting the threshold. Cardiomyocytes with a circularity ratio of
≥ 1.2 were excluded to eliminate cells sectioned tangentially [28].
Areas of at least 33 cells per animal were measured, and were scored
blind to surgeries and strain.
Heart wall thickness of the LV free wall was measured using AxioVision 4.7 software (Zeiss) in three distinct areas within and between the
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anterior and posterior regions of the free wall; three measurements
were taken from each area for a total of 9 averaged measurements per
sample. For the septal wall, single measurements were taken from
three distinct areas of the wall and averaged for each sample.

2.10. Statistical analysis
All data were analyzed using GraphPad Prism 6.01 (GraphPad). All
statistical analyses were performed using two-way ANOVA followed
by Bonferroni post-tests and presented as mean ± SEM. Differences
were considered signiﬁcant at P b 0.05.

2.7. Immunohistochemistry
3. Results
Immunohistochemical staining was performed on 5 μm thick parafﬁn heart sections. Samples underwent a deparafﬁnisation process and
antigen retrieval was carried out in sodium citrate buffer (pH 6.0) at
92 °C using a BP-111 laboratory microwave (Microwave Research and
Applications). Sections were incubated with primary antibody anti-6X
His tag-ChIP Grade (Abcam) overnight followed by biotinylated secondary antibody, and signal was detected using avidin-biotin complex
(ImmunoCruz ABC staining kit, Santa Cruz). Diaminobenzidine (DAB)
substrate solution was used for antigen visualization with haematoxylin
as a counterstain. Following staining, the LV free wall was imaged in
three distinct locations within and between the anterior and posterior
walls. Slides were imaged at 400× magniﬁcation with a Zeiss Observer
D1 microscope using AxioVision 4.7 software. To ensure accurate comparisons of antigen visualization, sections from WT and RGS2eb TG genotypes were stained simultaneously and all images were captured
using the same microscopic parameters.

2.8. Dot blotting
Using mechanical disruption (Sonic Dismembrator Model 100, Fisher Scientiﬁc), LV heart and kidney tissues from RGS2eb TG and WT mice
were lysed in 20 mM, pH 7.5 Tris-HCl buffer containing cOmplete Mini
protease inhibitor cocktail (Sigma). Samples were centrifuged at
100,000g for 1 h at 4 °C in an Optima TLX micro-ultracentrifuge
(Beckman Coulter), and supernatants were kept for experiments. Following protein concentration determination by Bradford assay, equal
amounts of sample protein were spotted directly on to Amersham
Protran 0.2 μm pore size nitrocellulose membrane (GE Healthcare Life
Sciences). Puriﬁed histidine-tagged RGS-16 (His-RGS16) was also dotted on to membranes to serve as a positive control. Dried membranes
were blocked in 5% milk-TBST, followed by overnight incubation in
1:2000 ChIP grade anti-6X Histidine primary antibody (Abcam) and
then 1:5000 goat anti-rabbit secondary antibody HRP conjugate
(Invitrogen). Signal was detected using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientiﬁc) and imaged with the
Versadoc MP 5000 system and Quantity One software (Bio-Rad).

2.9. Quantitative reverse transcription PCR
Total RNA was isolated from heart tissue using the TriZol
(Invitrogen) extraction method. Reverse transcription reaction was performed using the High-Capacity cDNA Reverse Transcription Kit with
RNase Inhibitor (Invitrogen). SensiFAST SYBR No-ROX Kit mastermix
(FroggaBio) was used for real-time thermal cycling. Primers for RGS2
(TGGGATTATGTGGCCTTAGC forward, AAGAACGTCAACACCCTTGC reverse), hGH (TGGGAAGACAACCTGTAGGG forward, AATCGCTTGA
ACCCAGGAG reverse), β-MHC (CTGAGACGGAGAATGGCAAGAC forward, ACTTGTTAGGGGTTGACGGTGAC reverse), ANP (ATTCCTGAGA
CGTCCCCTTT forward, CATTTCCATCCACAGCTCCT reverse), and BNP
(TGGGAATTAGCCATGTGAGAG forward, TTTGGGTGTTCTTTTGTGAGG
reverse) were designed using the OligoPerfect Designer (ThermoFisher),
OligoCalc [24] and Primer-BLAST (NCBI) programs. Samples were ampliﬁed for 35 cycles using the Eppendorf Mastercycler Realplex Real-Time
PCR machine. The mRNA quantity for each gene of interest was determined using standard curve analysis and normalized to 28S ribosomal
expression.

3.1. Generation of transgenic mice with cardiomyocyte speciﬁc expression
of RGS2eb
We previously demonstrated that the in vitro expression of RGS2eb
was sufﬁcient to inhibit drug-induced hypertrophy in isolated neonatal
rat cardiomyocytes [22]. To elucidate the potential in vivo protective
role of RGS2eb, we developed a novel strain of transgenic mice with
targeted myocardial overexpression of polyhistidine-tagged RGS2eb
under the control of the α-myosin heavy chain promoter (Fig. 1A).
Genotyping with primers for a portion of the hGH polyA region, which
was only present in the transgenic sequence of RGS2eb mice, was used
to differentiate between RGS2eb TG and wildtype mice. Both RGS2eb
TG and WT controls displayed a band at 342 bp indicating the presence
of endogenous full-length RGS2 (Fig. 1B); only RGS2eb transgenic mice
displayed an additional 293 bp band, which indicated the presence of
the hGH poly A region. Due to the short length of the RGS2eb transgene
and difﬁculty in immunoblotting [22], immunohistochemical staining,
qPCR for RGS2 and the human growth hormone (hGH), as well as dot
blot visualization for the polyhistidine tag were used to conﬁrm expression of the RGS2eb transgene. Following DAB visualization, WT mice
showed an absence of staining for polyhistidine, whereas RGS2eb TG
mice displayed positive antigen staining (Fig. 1C). Endogenous RGS2 appears to be decreased in both WT and RGS2eb TG mice following TAC
(Fig. 1D), which has been previously demonstrated [29], however this
was not statistically signiﬁcant. Expression of a region of hGH, which
should only be present in transgenic mice, is signiﬁcantly higher in
RGS2eb TG mice than in WT animals (Fig. 1E). In addition, LV heart tissues from RGS2eb TG mice showed positive signals for polyhistidine
when visualized on dot blots, whereas no signal was detected in noncardiac tissue (i.e. kidney) and LV samples from WT mice (Fig. 1F). Together, these results indicate successful generation of transgenic mice
with cardiomyocyte speciﬁc overexpression of RGS2eb.
3.2. Improved cardiac function in RGS2eb transgenic mice following pressure overload
Transverse aortic constriction (TAC) was used to induce experimental pressure overload on wildtype and RGS2eb TG hearts. Following
4 weeks of constriction, systolic pressure was signiﬁcantly increased in
the right carotid artery, but signiﬁcantly reduced downstream of the
TAC site in the left carotid artery in both WT and RGS2eb TG mice (Fig.
2A and B). This resulted in a 61 ± 10 mm Hg difference in maximal systolic pressure between the left and right carotid arteries of WT sham
and TAC mice, and a 62 ± 9 mm Hg difference between RGS2eb TG
sham and TAC mice (Fig. 2C). These data, as well as summary hemodynamic parameters in Table 1, conﬁrm that pressure overload had indeed
been induced upon TAC hearts. Increased vascular resistance was
reﬂected by signiﬁcantly higher end-systolic pressures in TAC mice; increased afterload as well as cardiac dilation or hypertrophy in TAC mice
was also indicated by signiﬁcant increases in the end systolic and end
diastolic volumes (Table 1). Heart rate under anaesthesia was maintained at similar levels in all surgery groups (Fig. 2D).
Following pressure-volume loop analysis, RGS2eb TG mice demonstrated improved cardiac function as measured by multiple systolic
and diastolic indices. Summary data for contractility and relaxation
(maximal elastance, ejection fraction, left ventricular systolic pressure,
arterial elastance, LV + dP/dt, LV − dP/dt, and time constant tau) are
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Fig. 1. Generation of transgenic mice with cardiomyocyte speciﬁc expression of RGS2eb. (A) Construct used for the generation of mice with cardiomyocyte-speciﬁc overexpression of RGS2eb under
the control of α-myosin heavy chain. (B) Genotyping for a region which includes the hGH PolyA sequence results in a positive band for RGS2eb TG mice and the absence of a band in WT controls
(lanes 8 and 10), while genotyping for endogenous RGS2 resulted in bands for both RGS2eb TG and WT controls (lanes 1, 3, 5, 7, and 9). (C) Representative immunostaining in the left ventricle of
WT mice shows an absence of polyhistidine staining, whereas RGS2eb TG mice display positive immunostaining for polyhistidine. (D) RGS2 and (E) hGH qPCR expression in WT and RGS2eb TG
mice following sham or TAC surgery. (F) Signal for polyhistidine was only detected in the LV tissue of RGS2eb TG mice and His-RGS16 positive controls, with no signal detected in non-cardiac tissue
or WT mice. Data represent means ± SEM, n = 5–6 per group. **P b 0.01, and ***P b 0.001 using two-way ANOVA with Bonferroni's post hoc test for multiple comparisons.

provided in Fig. 3. Notably, Millar catheter measurements of the maximal and minimal rates of pressure change in the left ventricle (LV +dP/
dt and LV −dP/dt, respectively), which are important indices of cardiac
contractility, were signiﬁcantly greater in RGS2eb TG TAC mice compared
to WT TAC counterparts (Fig. 3F and G). In addition, WT TAC mice showed
signiﬁcant increases in the Tau relaxation constant (Fig. 3H), indicating
impairment of active properties of diastolic relaxation [30]. These data
suggest that the functional deﬁcit in RGS2eb TG mice following 4 weeks
of TAC is reduced in comparison to WT TAC animals.
3.3. Cardiac hypertrophy is inhibited in RGS2eb transgenic mice following
pressure overload
Following 4 weeks of TAC, heart weight/body weight (HWT/
BWT) ratios, LV and septal wall thickness, and the cross-sectional

areas of cardiomyocytes were used to evaluate the development of
cardiac hypertrophy. Although WT TAC mice developed signiﬁcant
cardiac hypertrophy (as measured by HWT/BWT) compared to
sham controls, RGS2 eb TG mice displayed limited hypertrophic
growth compared to WT TAC animals (Fig. 4A). Some hypertrophy
does still appear to have occurred, as both WT and RGS2eb TG mice
exhibited signiﬁcantly increased LV free wall thickness compared
to corresponding sham controls (Fig.4B, 4F and 4G); Septal wall
thickness was not signiﬁcantly changed in TAC surgery groups compared to sham controls (Fig. 4C). In addition, RGS2eb TG TAC mice did
not show marked changes in LV free wall cardiomyocyte size compared to TG sham controls, and were signiﬁcantly smaller in size
than cardiomyocytes from WT TAC mice (Fig. 4D and H (representative)). No changes were observed in measured cardiomyocytes from
the septal wall (Fig. 4E). These data suggest that RGS2eb may confer a
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Fig. 2. Pressure overload model of transverse aortic constriction. (A) Following 4 weeks of aortic constriction between the left and right carotid arteries, systolic pressure in the LCA was
reduced while (B) systolic pressure in the RCA was signiﬁcantly increased. (C) Change in systolic pressure between the RCA and LCA following 4 weeks TAC was signiﬁcantly increased in
both WT and RGS2eb TG mice. (D) Heart rate remained at similar levels for all experimental and genotype groups. Data represent means ± SEM, n = 7–9 per group. *P b 0.05 and ***P b
0.001 using two-way ANOVA with Bonferroni's post hoc test for multiple comparisons.

protective effect in cardiomyocytes against pressure-induced cardiomyocyte hypertrophy.
3.4. Expression of cardiac hypertrophy markers is suppressed in RGS2eb
transgenic mice
Induction of “fetal” cardiac genes is often a common feature in animal models of pathological hypertrophy and heart failure [31,32]. RNA
was isolated from left ventricular tissue after 4 weeks of TAC or sham
surgery, and qPCR was performed to determine expression levels of βmyosin heavy chain (β-MHC), atrial natriuretic peptide (ANP), and
brain natriuretic peptide (BNP). WT mice which underwent TAC
showed signiﬁcantly increased levels of both β-MHC and ANP compared to sham controls (Fig. 5A and B). In contrast, β-MHC and ANP expression in RGS2eb TG mice after TAC was comparable to sham levels
(Fig.5A and 5B). BNP expression demonstrated a similar trend to that

Table 1
Hemodynamic parameters in 4 week sham and TAC mice. Data represent means ± SEM
**P b 0.05 and **P b 0.001 vs. sham controls using two-way ANOVA with Bonferroni's post
hoc test for multiple comparisons.
SHAM
n
BWT (g)
ESP (mmHg)
EDP (mmHg)
ESV (μL)
EDV (μL)
SV (μL)
SW (mmHg ∗ μL)
CO (μL/min)

WT
7–13
29.3 ± 1.0
98.2 ± 6.9
7.6 ± 1.4
18.4 ± 4.4
26.1 ± 3.3
19.9 ± 2.4
1456.9 ± 207
7112.3 ± 947

TAC
TG
6–13
30.7 ± 1.0
73.3 ± 14
6.0 ± 2.3
16.7 ± 0.5
25.9 ± 2.3
18.5 ± 2.6
1523.8 ± 187
6517.8 ± 907

WT
6–10
30.1 ± 0.6
134.1 ± 8.1*
15.0 ± 3.9
37.0 ± 5.9*
50.6 ± 7.5*
14.1 ± 2.1
1661.9 ± 207
6713.6 ± 596

TG
6–9
28.1 ± 1.0
144.2 ± 11**
15.5 ± 5.6
39.3 ± 6.5*
51.4 ± 6.2*
15.7 ± 2.7
1667.6 ± 231
8152.1 ± 1098

BWT, body weight; ESP, end systolic pressure; EDP, end diastolic pressure; ESV, end stroke
volume; EDV, end diastolic volume; SV, stroke volume; SW, stroke work; CO, cardiac
output.

seen with β-MHC and ANP, but this did not attain statistical signiﬁcance
between RGS2eb TG and WT mice after TAC (Fig.5C). Since the expression of fetal cardiac genes is postulated to be indicator of cardiac dysfunction, the absence of elevated levels in RGS2eb TG mice after TAC
suggests that the presence of RGS2eb is cardioprotective in a pressure
overload model of cardiac hypertrophy.
4. Discussion
In order for maladaptive cardiac hypertrophy to occur, individual
cardiomyocytes must increase in size; such growth requires increased
global protein synthesis, the rate of which is controlled primarily at
the initiation level [33]. Of particular importance is the heterotrimeric
initiation factor eIF2, which is activated by the heteropentameric protein eIF2B [34]. Notably, eIF2B has been shown to play a critical role in
the development of β-adrenergic receptor induced hypertrophy in cultured cardiomyocytes [35]. A major role for eIF2Bε in controlling cell
size is also evident from its regulation by glycogen synthase kinase 3β
(GSK3β), which constitutively phosphorylates eIF2Bε at serine 540 in
intact cells, thereby inhibiting its GEF activity by up to 80% [36]. In a cultured cardiomyocyte model, overexpression of a mutant eIF2Bε which
could not be phosphorylated by GSK3β increased cell size and abolished
the antihypertrophic effects of GSK3β, suggesting that eIF2Bε is a direct
mediator of cardiac myocyte hypertrophy [35]. Importantly, further expression of a dominant-negative mutant of eIF2Bε inhibited isoproterenol-induced cardiac hypertrophy, indicating the critical role of eIF2Bε in
protein synthesis and cell growth [35]. We have previously shown that
the cellular effects of eIF2Bε are blocked by RGS2eb as well as by full
length RGS2 [14,22]. The goal of the present study was to determine
whether the ability of RGS2 to inhibit protein synthesis and cardiomyocyte growth in vitro could be extended to an animal model of pathological cardiac hypertrophy. We therefore developed a mouse line with
cardiomyocyte speciﬁc expression of RGS2eb, and examined the functional, histological, and biochemical consequences of experimental
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Fig. 3. Indices of systolic and diastolic function. (A) Representative PV loops during preload reduction by inferior vena cava occlusion in sham (solid lines) and 4 week TAC animals (dotted
lines). (B) Slope of left upper relation (maximal elastance [Emax]) reﬂected contractile function. (C) Ejection fraction was signiﬁcantly reduced in WT but not RGS2eb TG mice following
pressure overload, while (D) LV systolic pressure (LVSP) was signiﬁcantly elevated following TAC in both WT and RGS2eb mice. (E) Effective arterial elastance (Ea; an index of total
ventricular afterload) was also increased following TAC. (F) LV +dP/dt and (G) −dP/dt were signiﬁcantly improved in RGS2eb mice following TAC, and (H) Tau relaxation time
constant remained comparable to sham groups. Data represent means ± SEM, n = 6–9 per group. *P b 0.05 and ***P b 0.001 using two-way ANOVA with Bonferroni's post hoc test for
multiple comparisons.

pressure overload in our transgenic mice and WT littermates. To the
best of our knowledge, this is the ﬁrst study to demonstrate that expression of a portion of RGS2, namely the RGS2eb binding domain, can reduce pathogenic growth without adversely affecting in vivo cardiac
function. Although a random insertion effect cannot be entirely excluded, expression of this transgene inhibited TAC-induced increases in
heart weight/body weight ratio (Fig. 4A) and expression of hypertrophy-related gene markers (Fig. 5), as well as associated functional loss
(Fig. 3). These results likely reﬂect the ability of RGS2eb to inhibit protein
synthesis in vivo, and the consequent suppression of the hypertrophic
response and cardioprotective effects.
Using qPCR, immunohistochemistry and dot blotting methods, we
have demonstrated the cardiac-speciﬁc expression of RGS2eb in our
transgenic mice (Fig.1). However, due to the short length of the
RGS2eb transgene and difﬁculty in immunoblotting [22], a limitation of
our study is our inability to fully demonstrate an eIF2B-RGS2eb complex.
Although RGS2eb expression is associated with a decrease in cardiac hypertrophy and improved cardiac function, and our previous in vitro
studies suggest that this is due to the inhibition of eIF2Bε, we cannot deﬁnitively attribute our in vivo observations to the direct inhibition of

protein synthesis, and thus cannot exclude other off target effects as
the mechanism behind our observed cardioprotection.
Although LV free wall thickness was signiﬁcantly increased in both
WT and RGS2eb TG mice following 4 weeks of TAC (Fig. 4B), HWT/
BWT ratios indicated the development of signiﬁcant TAC-associated cardiac hypertrophy in WT, but not RGS2eb TG mice (Fig. 4A). Furthermore,
measurements of cardiomyocyte cross-sectional area showed a corresponding increase in cell size for WT TAC but not RGS2eb TG mice (Fig.
4D). These data suggest that de novo protein synthesis in response to
pressure overload, and thus hypertrophy, is inhibited in RGS2eb TG
mice.
Our previous work showed that the adenoviral expression of RGS2eb
in neonatal ventricular myocytes was able to attenuate the expression
of genetic markers of hypertrophy to a comparable extent as full-length
RGS2 [22]. Thus, we examined whether RGS2eb could also attenuate in
vivo increases in the “fetal gene program”, a group of molecular markers
associated with the hypertrophy phenotype, including β-MHC, ANP,
and BNP [37–39]. Four weeks of aortic constriction induced an increase
in the levels of β-MHC and ANP in WT mice (Fig. 5). These increases
were completely abrogated in RGS2eb TG animals. Reactivation of fetal
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Fig. 4. Cardiac hypertrophy is inhibited in RGS2eb transgenic mice following pressure overload. (A) After 4 weeks of aortic constriction, cardiac hypertrophy in RGS2eb TG mice was
signiﬁcantly less than WT TAC. (B) LV free wall thickness was increased in both TAC groups; (C) septal wall thickness did not increase. (D) Cardiomyocyte size was signiﬁcantly
reduced in RGS2eb TG mice compared to WT TAC in the LV free wall, with (E) no noticeable changes to size in the septal wall. (F) Representative whole hearts for WT and RGS2eb TG
mice following 4 weeks of sham or TAC surgery. (G) Representative H&E staining of WT and RGS2eb LV cross sections of WT and RGS2eb TG cardiomyocytes following sham or TAC
surgery. (H) Representative H&E staining of WT and RGS2eb cardiomyocytes. Data represent means ± SEM, n = 6–13 per group. *P b 0.05, **P b 0.01, and ****P b 0.0001 using twoway ANOVA with Bonferroni's post hoc test for multiple comparisons.

gene expression during cardiac hypertrophy is initially an adaptive process which increases the excitability, contractility, and plasticity of cardiac myocytes in response to pathological stress [40]. However,
sustained fetal gene expression plays a causative role in maladaptive
cardiac remodelling, leading to cardiac dysfunction and often the pathogenesis of heart failure [41]. In addition, our assessment of cardiac
function obtained from pressure-volume loop analyses also suggests
that RGS2eb TG mice were able to maintain signiﬁcantly improved cardiac function after TAC compared to WT mice, as evidenced by both systolic and diastolic indices (Fig. 3). Our data suggest that the expression
of RGS2eb appears to not only inhibit cardiac hypertrophy, but also

improves cardiac function without activation of fetal cardiac genes
after 4 weeks of TAC, although the effect on fetal gene expression may
more likely be due to an indirect effect of the inhibition of cardiac hypertrophy and apparent improvement in cardiac function, rather than a direct mechanistic connection between RGS2eb and the re-expression of
fetal genes. Further studies, such as prolonged exposure to TAC, may
clarify the extent to which these effects are sustained.
Following transverse aortic constriction, RGS2 knockout mice have
been found to develop severe cardiac hypertrophy and heart failure, as
well as increased mortality compared to corresponding controls [15].
Although this clearly indicates that the presence of RGS2 is
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Fig. 5. Markers of cardiac hypertrophy. (A) β-MHC expression was signiﬁcantly increased in WT TAC but not RGS2eb TG mice after 4 weeks of aortic constriction. (B) ANP expression was
also signiﬁcantly elevated in WT TAC mice, while RGS2eb TG mice maintained near-sham levels of expression. (C) BNP expression. Data represent means ± SEM, n = 4–8 per group. *P b
0.05, **P b 0.01, and ***P b 0.001 using two-way ANOVA with Bonferroni's post hoc test for multiple comparisons.

cardioprotective in vivo, many details of this beneﬁcial effect remain to
be elucidated [22]. In cultured ventricular myocytes, RGS2 is acutely
and selectively upregulated in response to activators of Gq and Gs signalling [13,14,42]. However, RGS2 has been found to be ultimately downregulated in vivo following experimentally-induced hypertrophy and
heart failure [29]. Furthermore, cardiac-speciﬁc overexpression of fulllength RGS2 does not result in demonstrable cardioprotective effects
in mice subjected to TAC [43]. Conversely, the overexpression of either
RGS4, RGS5, or RGS10 has been shown to reduce cardiac hypertrophy
[44–47], although it may be noted that unlike RGS2, these proteins
tend to localize to the atria rather than the ventricles [46,48–51]. It is
possible that the optimal level of RGS2 is decreased under conditions
of hypertrophic stress, however a complete lack of RGS2 is clearly detrimental under pressure overload [15].
The lack of an observable protective effect of full-length RGS2 overexpression in the myocardium [43] stands in contrast to the present
ﬁndings that expression of its isolated eIF2B-interacting domain
(RGS2eb) can protect against pathological cardiac hypertrophy and dysfunction in vivo. We have previously shown that the ability of RGS2eb to
inhibit drug-induced cell hypertrophy is independent of the G protein
inhibitory effects of full-length RGS2 [22]. Along with our current ﬁndings, it follows that the RGS2eb region may be an important contributor
to the reported beneﬁcial cardiac effects of RGS2. Since our previous
studies suggest that the RGS2eb region speciﬁcally binds to eIF2B and
thereby inhibits protein synthesis [19], it is possible that some function
of full length RGS2 may produce detrimental effects in the context of
pathological hypertrophy, consistent with its observed downregulation
in the latter condition [29]. Negative RGS2 effects could conceivably
arise from its inhibition of beneﬁcial G protein-mediated signals (e.g.
the protective effects of adenosine) or alternatively via its effects on
non-G protein targets such as tubulin or TRP channels [16,17]. To examine the importance of the RGS2eb region per se, future studies would be
in order, with expression of this truncated form targeted to the myocardium of full-body or cardiac-speciﬁc RGS2 knockout mice.

5. Conclusions
The present results suggest that expression of the eIF2B-interacting
domain of RGS2, RGS2eb, can protect against pathological cardiac hypertrophy and dysfunction in vivo, and that this may be via the direct inhibition of protein synthesis. We have previously shown the ability
of RGS2eb to inhibit drug-induced cardiomyocyte hypertrophy;
along with our current ﬁndings, this suggests that the RGS2eb region is
an important contributor to the reported beneﬁcial cardiac effects of
RGS2.
Currently, the majority of drugs for cardiovascular diseases target
GPCRs. Although these medications can offer signiﬁcant beneﬁts to
patients, heart failure continues to be a global leading cause of morbidity and mortality. A better understanding of the various components that are part of the GPCR signalling pathways may lead to
improved therapeutics, and interest in RGS2 and other RGS proteins
as possible drug targets is on the rise [52–58]. In summary, this study
has demonstrated that RGS2eb is important in regulating in vivo cardiac hypertrophy and physiology, and suggests that this region of
full-length RGS2 may be a key component of its reported cardioprotective
effects.
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